**Amber N. Pepper, M.D.**


University of South Florida, Morsani College of Medicine, Tampa, Florida

**CONTACT INFORMATION**

University of South Florida Joy McCan Culverhouse Asthma, Allergy, and Immunology Clinical Research Unit13801 Bruce B. Downs Blvd., Suite 505

Tampa, FL 33613

Phone: (813) 631-4024, Ext. 200

Fax: (813) 631-4030

Allergy, Asthma & Immunology Associates of Tampa Bay (AllergyTampa.com) 13801 Bruce B. Downs Blvd., Suite 502

Tampa, FL 33613

08-NOV-2024

Phone: (813) 971-9743

Fax: (813) 558-9421

Website: allergytampa.com

University of South Florida Morsani Center for Advanced Healthcare

13330 USF Laurel Drive  
Tampa, FL 33612

Phone: (813) 821-8033

Fax: (813) 974-7550

**Academic email:** [apepper1@usf.edu](mailto:apepper1@usf.edu)

**CITISENSHIP**

US Citizen

**EDUCATION**

**Doctor of Medicine**  2009 – 2013University of South Florida Morsani College of Medicine, Tampa, FL

Class rank: 1/107

Research scholarly concentration, AOA junior inductee

**Bachelor of Science in Integrative Biology** 2005 – 2009 University of Florida, Gainesville, FL

GPA: 4.00/4.00; Cum laude

Minor in Nutritional Sciences, Financed 100% of tuition through merit-based Bright Futures Scholarship

**POSTGRADUATE TRAINING**

**University of South Florida** **Allergy and Immunology Fellowship** 2016 – 2018 13000 Bruce B. Downs. Blvd. (111D)

Tampa, FL 33612

Phone: (813) 972-7631

2nd Year Chief Fellow

American Board of Allergy and Immunology (ABAI) certified 2018 – Present

Participating in MOC

**University of South Florida Internal Medicine Residency** 2013 – 2016

17 Davis Blvd., Suite 308

Tampa, FL 33606

Phone: (813) 259-0697

3rd Year Chief Resident

American Board of Internal Medicine (ABIM) certified 2016 – Present

Participating in MOC

**LICENSES AND CERTIFICATIONS**

Florida Medical License: ME 126769 2016 – Present

Participating in MOC

ABAI and ABIM certified

BLS Certified Through March 2025

**HONORS AND AWARDS**

Castle Connolly Top Doctor 2025

TAMPA magazine “Top Doctors” winner 2019, 2020, 2021, 2022, 2023, 2024

Food Allergy Research and Education Clinical Research Center of Distinction 2020, 2021, 2022, 2023, 2024

USF Internal Medicine Chairman’s Leadership Award 2016

Awarded for excellence in balancing competing demands while improving the residency program

American College of Physicians Florida Chapter Chief Resident Award 2016

USF Internal Medicine Resident of the Month 2014

AAAAI Chrysalis Project 2014

Roy H. Behnke, MD Award 2013

College of Medicine Dean’s Award 2013

Awarded to the student first in their class after 4 years of medical school

Academic Excellence Award 2013

Alpha Omega Alpha Honor Medical Society 2012

Junior inductee, Gamma Chapter

D.L. Smith Charter Class Scholarship 2012

Awarded to the student first in their class after 3 years of medical school

Commendation for Clinical Excellence 2012

Martin and Ruth Silbiger Endowed Scholarship 2011

Awarded to the student first in their class after 2 years of medical school

USF Health Morsani College of Medicine Merit Scholarship 2011

USF Health Morsani Office of Educational Development Summer Research Stipend 2010

**APPOINTMENTS**

**Academic**

**Associate Professor of Medicine and Pediatrics** 2024 – Present

University of South Florida, Tampa, FL

Department of Internal Medicine, Division of Allergy and Immunology

**Director,** **Joy McCan Culverhouse** **Clinical Research Unit**  2024 – Present University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit, Tampa FL

**FARE Primary Investigator and Director, Clinical Research Center of Distinction**  2020 – Present

Food Allergy Research and Education (FARE)

University of South Florida, Department of Internal Medicine, Division of Allergy and Immunology

**Associate Director, Clinical Research Unit**  2019 – 2024

University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit, Tampa FL

**Assistant Professor of Medicine and Pediatrics** 2018 – 2024

University of South Florida, Tampa, FL

**Co-Director, USF Symposium Update in Allergy and Immunology** 2019 – 2020

Facilitated lecturers, sponsorships, accreditation, and attendance at symposium

**Hospital**

Tampa General Hospital, Tampa, FL 2018 – Present

James A. Haley VA Hospital, Tampa, FL 2018 – Present

Moffitt Cancer Center, Tampa, FL 2018 – Present

**Clinical**

Allergy, Asthma & Immunology Associates of Tampa Bay, Tampa, FL 2018 – Present

USF-affiliated clinical practice

**TEACHING, LECTURE**

**USF Morsani College of Medicine Doctoring 2 Faculty Preceptor**  2018 – 2019

Taught clinical reasoning, physical exam, professionalism, and ethics to 2nd year medical students

**TEACHING, SUPERVISATORY**

**Doctoring Clinical Experience (DCE) Preceptor** 2019 – Present

Teach clinical skills to 1st and 2nd year medical students during clinic in a hands-on manner

**USF Allergy and Immunology Fellowship Faculty Educator**  2018 - Present

Lead weekly ABAI board preparation sessions with the fellows

Give bi-annual literature review lectures, and 2-3 educational lectures per year on A/I topics to fellows and faculty: hereditary angioedema, inhaler technique, food allergy, and chronic urticaria

Supervise fellows and IM residents in clinical practice, inpatient consults, and the Clinical Research Unit

As Associate Director of the USF Asthma, Allergy, and Immunology Clinical Research Unit, created a formal curriculum for fellows which is included in the fellowship handbook

Co-lead A/I board review for internal medicine residents

**LECTURES BY INVITATION**

“Pharmacologic Management of Atopic Dermatitis” March 27, 2025

USF Sanofi Educational Preceptorship; Tampa, FL

“Billing and Reimbursement for Nasal Allergen Challenges” March 1, 2025

WAO/AAAAI Annual Scientific Meeting; San Diego, CA

“Advances in Food Allergy Diagnosis and Treatment” January 17, 2025

USF Symposium Update in Allergy and Immunology; Tampa, FL

“Epidemiology and Pathophysiology of Food Allergy” May 1, 2024

Insights in Food Allergy and Urticaria Preceptorship; Tampa, FL

“Diagnosis and Clinical Manifestations of IgE‐mediated Food Allergy” May 1, 2024

Insights in Food Allergy and Urticaria Preceptorship; Tampa, FL

“Food allergy oral immunotherapy with case discussion” May 1, 2024

Insights in Food Allergy and Urticaria Preceptorship; Tampa, FL

“Chronic inducible urticarias with case discussions” April 30, 2024

Insights in Food Allergy and Urticaria Preceptorship; Tampa, FL

“Food Allergy and Intolerance” February 29, 2024

USF Grand Rounds

“Oral Food Allergen Immunotherapy” January 19, 2024

USF Symposium Update in Allergy and Immunology; Tampa, FL

“Oral Food Immunotherapy” January 20, 2023

USF Symposium Update in Allergy and Immunology; Tampa, FL

“Atopic Dermatitis and Food Allergy” January 6, 2023

Inaugural Eastern Food Allergy and Comorbidity Conference; Palm Beach, FL

“Food Immunotherapy” January 21, 2022

USF Symposium Update in Allergy and Immunology; Tampa, FL

“IgE-Mediated vs Non-IgE-Mediated Food Reactions (PBL)” January 17, 2020

USF Symposium Update in Allergy and Immunology; Tampa, FL

“Inhaler Technique” January 17, 2019

USF Symposium Update in Allergy and Immunology; Tampa, FL

**SCHOLARLY ACTIVITY**

1. **Current Grants**

**Agency: Nocion Therapeutics**

**I.D.#: NOC110-C-202**

**Title: “**A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: Funding on patient basis**

**Project period: 2024 – Present**

**Agency: Novartis**

**I.D.#:** CLOU064M12301

**Title: “**A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: Funding on patient basis**

**Project period: 2023 – Present**

**Agency: Novartis**

**I.D.#: CQGE031G12301 and CQGE031G12303B**

**Title: “**A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $62,007.85**

**Project period: 2022 – Present**

**Agency: Regeneron**

**I.D.#: R668-AD-1434**

**Title: “An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥ 6 months to <18 years of age with atopic dermatitis”**

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $314,863.63**

**Project period: 2018 – Present**

1. **Past Grants**

**Agency: UCB**

**I.D.#: UP0110**

**Title: “A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY,**

**PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE**

**ATOPIC DERMATITIS (PART B)”**

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: TBD**

**Project period: 2024 – 2025**

**Agency: Pfizer**

**I.D.#: B7451015**

**Title: “**A phase 3 study to Evaluate Efficacy and Safety of PF-04965842 (abrocitinib; JAK1 inhibitor) With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $56,609.00**

**Project period: 2019 – 2024**

**Agency: Florida High Tech Corridor Counil’s Matching Grants Research Program**

**I.D.#: FHT 20-05 Molekule**

**Title: “A Placebo-controlled Trial of the Molekule Air Purifier in the Treatment of Pet Allergy”**

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $93,386 (awarded)**

**Project period: 2019 – 2024**

**Agency: Gilead Sciences, Inc.**

**I.D.#: GS-US-556-5960**

**Title: “**A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Tirabrutinib (BTK inhibitor) in Subjects with Antihistamine-Resistant Chronic Spontaneous Urticaria”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $16,499.99**

**Project period: 2022 – 2022 (closed early by sponsor)**

**Agency: Regeneron**

**I.D.#: R668-AD-1539B**

**Title: “A phase 2/3 study to evaluate the safety, pharmacokinetics, and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis”**

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $97,336.84**

**Project period: 2018 – 2022**

**Agency: Regeneron**

**I.D.#: R3500-AD-1798**

**Title: “**Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis”

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $22,500.00**

**Project period: 2020 – 2020 (closed early by sponsor)**

**PUBLISHED BIBLIOGRAPHY**

**Peer-Reviewed Publications**

1. **Pepper AN.** Atopic Dermatitis and Food Allergy: To Test or Not To Test. *J Food Allergy*. 2023;5(1):25–28. PMID: 39022331.
2. **Pepper AN**, Casale TB. Is it time to set the alarmins as potential targets in food allergy? *Ann Allergy Asthma* *Immunol.* 2023;131(1):6-8.
3. Cho SH, Nanda A, Keswani A, Adinoff A, Baroody FM, Bernstein JA, Gherasim A, Han JK, Koepke JW, Ledford DK, **Pepper AN**, Rondón C, Schiffman A, Wagenmann M, Campo P; Rhinitis, Rhinosinusitis, and Ocular Allergy Committee of the AAAAI. Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective-a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee. *J Allergy Clin Immunol.* 2023;151(5):1215-1222.e4.
4. Paller AS, Simpson EL, Siegfried EC, **participating investigators**, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2022;400(10356):908-919.
5. Georas SN, Wright RJ, Ivanova A, **PrecISE Study Team**, et al. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. *J Allergy Clin Immunol.* 2022;149(2):488-516.e9.
6. Westermann-Clark E, **Pepper AN**, Lockey RF. Anaphylaxis: Access to Epinephrine in Outpatient Setting. *Immunol Allergy Clin North Am*. 2022;42(1):175-186.
7. **Pepper AN**, Sriaroon P, Casale TB. Emerging developments in the forefront of peanut oral immunotherapy. *Curr Opin Allergy Clin Immunol.* 2021; 21(3):263-268.
8. **Pepper AN**, Hanania NA, Humbert M, Casale TB. How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. *J Allergy Clin Immunol Pract*. 2021; 9(3): 1081-8.
9. **Pepper AN**, Sriaroon PS, Glaum MC. Food Allergy Primer: Additives and preservatives: Role in food allergy. *J Food Allergy*. 2020;2(1): 119-123. doi: 10.2500/jfa.2020.2.200014.
10. **Pepper AN**, Assa'ad A, Blaiss M, Brown E, Chinthrajah S, Ciaccio C, et al. Consensus Report from the Food Allergy Research and Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. *J Allergy Clin Immunol*. 2020; 146(2):244-249
11. **Pepper AN**, Bulkhi A, Smith CR, Collis M, Bergmann KC, Zuberbier T, Casale TB. Effects Of Exposure To New Car Interiors In Patients With Asthma And Allergic Rhinitis. *Allergy Rhinol (Providence)*. 2018; 9: 1-4.
12. Westermann-Clark E, **Pepper AN**, Lockey RF. Economic considerations in the treatment of systemic allergic reactions*. J Asthma Allergy*. 2018; 11:153-158.
13. **Pepper AN**, Ledford DK. Nasal and Ocular Challenges. *J Allergy Clin Immunol*. 2018;141(5):1570-1577.
14. Saco TV, **Pepper A**, Casale TB. Uses of biologics in allergic diseases: What to choose and when. *Ann Allergy Asthma Immunol*. 2018;120(4):357-366.
15. **Pepper AN**, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. *J Allergy Clin Immunol Pract.* 2017; 5(4):909–916.
16. Chen J, Zhou Y, Zhang L, Wang Y, **Pepper AN**, Cho SH, et al. Individualized Treatment of Allergic Rhinitis According to Nasal Cytology. *Allergy Asthma Immunol Res*. 2017; 9(5):403-409.
17. Saco TV, **Pepper AN**, Lockey RF. Benralizumab for the Treatment of Asthma. *Expert Rev Clin Immunol.* 2017;13(5):405-413.
18. **Pepper AN**, Westermann-Clark E, Lockey RF. The high cost of epinephrine autoinjectors and possible alternatives*. J Allergy Clin Immunol Pract.* 2017; 5(3):665-668.
19. **Pepper AN**, Calderón MA, Casale TB. Sublingual Immunotherapy for the Polyallergic Patient. *J Allergy Clin Immunol Pract*. 2017: 5(1):41-45.
20. **Pepper AN**, Cooke A, Livingston L, Lockey RF. Asthma and chronic obstructive pulmonary disease inhalers: techniques for proper use. *Allergy Asthma Proc*. 2016; 37(4):279-90.
21. Westermann-Clark E, **Pepper AN**, Talreja N, Lockey RF. Debunking myths about "allergy" to radiocontrast media in an academic institution. *Postgrad Med.* 2015; 127(3):295-300.
22. **Pepper AN**, Valenzuela MO, Oller KL. Aortoduodenal Fistula in a Patient on Intravitreal Bevacizumab Injections: A Case Report. *Am J Ther.* 2015; 22(3):e75-6.
23. **Pepper AN**, Talreja N, Cowan GM, Glaum MC and Lockey RF. Lymphopenia Induced by Etanercept. *Ann Allergy Asthma Immunol*. 2014; 112(3):262-3.

**Book Chapters**

1. Tolliver S, **Pepper AN**, Pothiawala S, and Silverberg NB. (2021). Pediatric Psoriasis and Therapy. In JM Weinberg and M Lebwohl (Eds.) *Advances in Psoriasis*. (pp. 311-342). Switzerland: Springer Nature.
2. **Pepper AN**, Ledford DK. (2016). Allergic Rhinitis: Diagnosis and Treatment. In Mahmoudi M (Ed.) *Allergy and Asthma: Practical Diagnosis and Management, 2nd edition*. (pp. 63-85). Switzerland: Springer International Publishing.
3. **Pepper AN**, Pothiawala S, and Silverberg NB. (2014). Pediatric Psoriasis and Therapy. In JM Weinberg and M Lebwohl (Eds.) *Advances in Psoriasis: A Multisystemic Guide*. (pp. 253-276). London: Springer.

**Abstracts and Poster Presentations**

1. Alwawi Y, Patadia R, **Pepper AN**. You Can’t Avoid The Dentist Forever: A Rare Case of Plasma Cell Gingivitis. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Boston, MA on October 26, 2024.
2. Patadia R, **Pepper AN**. More Than Skin Deep: A Case of Acute Localized Exanthematous Pustulosis Following a Cosmetic Procedure. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Boston, MA on October 26, 2024.
3. Patel BR, Hudey S, and **Pepper AN**. Natural Does Not Always Mean Safer - A Case of Systemic Reaction from Bee Pollen. Florida Allergy, Asthma, and Immunology Society Annual Meeting in Orlando, FL on July 15, 2023.
4. Ishmael L, Imanirad D, **Pepper AN.** Monkeying Around: Chronic Urticaria and Angioedema Secondary to *Strongyloides*. Southeastern Allergy, Asthma and Immunology Society Annual Conference in St. Simons Island, GA on September 17, 2022.
5. Shepard KV, **Pepper AN**, Ledford DK. No Fun In Fungi: A Case of Allergic Fungal Rhinosinusitis. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Seattle, WA on November 16, 2018.
6. **Pepper AN**, Bulkhi A, Smith CR, Collis M, Zuberbier T, Casale TB. Effects Of Exposure To New Car Interiors On Patients With Asthma And Allergic Rhinitis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Orlando, FL on March 5, 2018.
7. Hudey S, **Pepper AN**, Wong K, Glaum M, Lockey RF. Systemic Mastocytosis Masquerading as Eosinophilic Gastroenteritis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Orlando, FL on March 2, 2018.
8. **Pepper AN**, Ledford DK, Lockey RF. Angioedema Vanishing Into Thin Air. USF Health Research Day in Tampa, FL on February 24, 2018.
9. **Pepper AN**, Ledford DK, Lockey RF. Angioedema Vanishing Into Thin Air. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Boston, MA on October 27, 2017.
10. **Pepper AN**, Ricketti PA, Glaum MC, Lockey RF. Hypogammaglobulinemia in a Patient with Stevens-Johnson Syndrome and Follicular Lymphoma. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in San Francisco, CA on November 11, 2016.
11. **Pepper AN**, Westermann-Clark E, Talreja N, and Lockey RF. Rectifying Misconceptions About Shellfish Allergy and Iodine “Allergy” In An Academic Institution. American Academy of Allergy, Asthma & Immunology Annual Meeting in San Diego, CA on March 4, 2014.
12. **Pepper AN**, Westermann-Clark E, Talreja N, and Lockey RF. Radiocontrast Media Reactions: Fact Versus Fiction. American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Baltimore, MD on November 9-10, 2013.
13. Chuong FS, **Nardandrea A**, Silva CP, and Plosker S. Letrozole induced ovulation and pregnancies in anovulatory clomiphene citrate-resistant women. American Society of Reproductive Medicine Annual Meeting in San Diego, CA on October 23, 2012.
14. **Nardandrea A** and Plosker S. Efficacy of an aromatase inhibitor in achieving ovulation and pregnancy in clomiphene citrate-resistant women. USF Health Research Day in Tampa, FL on February 25, 2011.

**Oral Abstracts/Presentations**

1. **Pepper AN**, Lockey RF, Sriaroon P. Absent B cells and Hypogammaglobulinemia in an Adolescent with Granulomatosis with Polyangiitis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Atlanta, GA on March 4, 2017.

**Other Publications**

1. **Pepper AN**, Lockey RF.Angioedema: Two Kinds, Different Outcomes. *The Bulletin of the Hillsborough County Medical Association*. 2018; 64:22-23.
2. **Pepper AN**, Updegraff A, and Lockey RF. (2015, July). Fatigue and generalized pruritus. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.
3. **Pepper AN**, Salim N, and Lockey RF. (2014, April). Recurrent sinopulmonary infections. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.
4. **Pepper AN**, Aljubran SA, and Lockey RF. (2013, May). Recurrent attacks of anaphylaxis. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.

**OTHER RESEARCH AND CREATIVE ACHIEVEMENTS**

**USF Asthma, Allergy, and Immunology Clinical Research Unit**

**Principal Investigator:**

1. Novartis CLOU064M12301 2023 – Present

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines

1. UCB BioSciences UP0110 2023 – Present

Phase 1/2A study to investigate the safety, pharmacokinetics, and efficacy of UCB1381 (IL-22 and IL-13 antagonist) in study participants with atopic dermatitis (Part B)

1. Novartis CQGE031G12303B 2023 – Present

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

1. Novartis CQGE031G12301 2022 – 2023

A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

1. Regeneron R668-AD-1434 2018 – Present

An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥ 6 months to <18 years of age with atopic dermatitis

1. Pfizer B7451015 2019 – 2024

A phase 3 study to Evaluate Efficacy and Safety of PF-04965842 (abrocitinib; JAK1 inhibitor) With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

1. Molekule 2019 – 2024

Industry-sponsored prospective, blinded, proof of concept study assessing air purifier effects on subjective and objective measures of asthma and allergic rhinitis in pet-sensitive subjects

1. Regeneron R668-AD-1539B 2018 – 2022

A phase 2/3 study to evaluate the safety, pharmacokinetics, and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis

1. Gilead GS-US-556-5960 2022

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Tirabrutinib (BTK inhibitor) in Subjects with Antihistamine-Resistant Chronic Spontaneous Urticaria.

1. Regeneron R3500-AD-1798 2020

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

**Sub-Investigator:**  2016 – Present

1. DBV (VITESSE): A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy
2. ALK (PT01): A phase I open-label trial to assess the tolerability and safety of an up-dosing regimen with a once-daily peanut SLIT-tablet in adults, adolescents, and children with peanut allergy
3. Allergy Therapeutics (VLP-Peanut101): A Phase I clinical trial to evaluate the safety and tolerability of VLP Peanut in healthy subjects and subjects with peanut allergy and to explore preliminary signals of its efficacy (PROTECT)
4. ARS Pharmaceuticals (EPI-A01): A phase 2, single-dose, randomized, active and placebo controlled, cross-over study of the safety and efficacy of intranasal epinephrine after administration of ARS-1 or albuterol in subjects with persistent asthma
5. Alladapt (ADP101): An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)
6. A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines
7. Master protocol of two randomized, double-blind, placebo-controlled, multi-center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab--EFC16461
8. Mercedes: Evaluation of mucous membrane tolerability of vehicle components and their manufacturing materials

A prospective study evaluating mucous membrane tolerability of vehicle components and manufacturing materials in subjects with asthma and allergic rhinitis - Presented abstract and wrote (first author) manuscript published in a peer-reviewed journal

1. Open-label extension study of omalizumab in patients with chronic rhinosinusitis with nasal polyps, WA40169
2. A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of dupilumab in patients aged ≥6 months to <6 years with severe atopic dermatitis, R668-AD-1539
3. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients, ≥6 years to <12 years of age, with severe atopic dermatitis, R668-AD-1652
4. Patient empowered strategy to reduce asthma morbidity in highly impacted populations (PREPARE)
5. A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects, B7451014
6. Chronic refractory cough cohort study (COCO)
7. Losartan effects on emphysema progression (LEEP)
8. Parental response using a daily digital diary to capture respiratory symptoms in young children with recurrent respiratory tract illnesses (American Lung Association [ALA] Novel Digital Diary [ANDDI])
9. Asthma BMI baseline study (ABBS)
10. A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of chronic spontaneous urticaria (CSU) in adolescents and adults inadequately controlled with h1-antihistamines, CQGE031C2302
11. A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to severe asthma, CCJM112X2204
12. A phase 2, multicenter, randomized, double-blind, placebo-controlled pilot and dose-ranging study of gdc-0853 in patients with refractory chronic spontaneous urticaria (CSU), GS39684
13. A phase 2 open-label extension study to evaluate the long-term safety and efficacy of fenebrutinib in patients previously enrolled in a fenebrutinib chronic spontaneous urticaria study, GS40868
14. Help study extension: an open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE), DX-2930-04
15. Real-world ar101 market-supporting experience study in peanut-allergic children, active treatment arm open-label extension study (RAMSES OLE), ARC011
16. A multicenter, open-label, long-term safety study of AR101 characterized oral desensitization immunotherapy in subjects who participated in a prior AR101 study, ARC008
17. Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE) follow-on study, ARC004
18. Real-world AR101 market-supporting experience study in peanut-allergic children ages 4 to 17 years (RAMSES), ARC007
19. A phase 2, multicenter, randomized, double-blind, placebo-controlled study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of dupilumab as adjunct to AR101-CODIT (peanut oral immunotherapy), R668-ALG-16114
20. A study to evaluate the efficacy and safety of dupilumab monotherapy in pediatric patients with peanut allergy, R668-ALG-1702
21. A phase 3, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with chronic rhinosinusitis with nasal polyps, GA39855
22. A double-blind, randomized, placebo-controlled study of the efficacy and safety of three doses of orvepitant in subjects with chronic refractory cough, VOLCANO-2

**USF Division of Allergy and Immunology**  2012 – 2015

Faculty Advisor: Richard F. Lockey, MD

Sub-investigator and author in a prospective survey study examining misconceptions about reactions to contrast media, shellfish, and iodine - Prepared the protocol, completed the IRB application, collected data, drafted and presented abstracts and posters, and helped write manuscript published in a peer-reviewed journal

**SERVICE**

**Committees**

**USF Search Committee: Open Rank Pulmonologist - Job ID: 34884** 2023 – Present

Faculty member and interviewer for filling pulmonology basic or physician scientist position

**USF Division of Allergy and Immunology Program Evaluation Committee**  2019 – Present

Faculty member; evaluate fellowship program and implement changes to enhance training experience

**USF Division of Allergy and Immunology Clinical Competency Committee**  2019 – PresentFaculty member; provide and review feedback of clinical training for fellows

**Community Service**

**WOC Volunteer Physician at James A. Haley VA Hospital**  2018 – Present

Provide medical services to veterans and supervision of medical trainees

**BRIDGE and Judeo-Christian Clinics** 2010 – 2016

Provided much-needed medical care for the underserved of Tampa Bay

**Project World Health**  2010

Raised funds and provided medical care to the people of the Jarabacoa region of the Dominican Republic

**FARE’s Investigator Awards Program Reviewer** 2024

Invited reviewer for new investigator funding applications for food allergy research

**AAAAI Work Group Report Author** 2022 – 2023

Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective- a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee

**Manuscript Reviewer**

PLOS ONE; the Journal of Allergy and Clinical Immunology: In Practice; Journal of Food Allergy; Annals of Allergy, Asthma & Immunology; USF IMPACT

**Professional Society Memberships**

Florida Medical Association 2023 – Present

Florida Allergy, Asthma, and Immunology Society 2019 – Present

Member; New Allergist Committee

American Academy of Allergy, Asthma, and Immunology (AAAAI) 2016 – Present

Fellow; AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee

American College of Allergy, Asthma, and Immunology 2016 – Present

Fellow